Literature DB >> 7487450

Decreased isokinetic trunk muscle strength and performance in long-term survivors of childhood malignancies: correlation with hormonal defects.

K K Talvensaari1, A Jämsen, H Vanharanta, M Lanning.   

Abstract

OBJECTIVE: To evaluate trunk muscle strength and performance in long-term survivors of childhood malignancies relative to age and sex-matched controls, and to relate the muscle strength observations to the therapeutic agents used and possible hormonal disturbances.
DESIGN: Age and sex-matched cohort study.
SETTING: Referral center in the northern part of Finland. PATIENTS: Forty-six long-term survivors of childhood cancer. Mean age at examination 19.1 years and median off-therapy time 9.4 years. INTERVENTION: Isokinetic dynamometer testing. MAIN OUTCOME MEASURES: Measurements of trunk muscle peak torque (PT) and total work done (TWD) were performed at angle speeds of 50 degrees/sec and 200 degrees/sec. The results were normalized relative to body fat-free weight (FFW).
RESULTS: PT in the trunk muscles was lower in the patients at both angle speeds (mean normalized PT = 5.7Nm/kgFFW vs 7.6Nm/kgFFW for controls at 50 degrees/sec), as also was TWD except for extension TWD at the higher angle speed (mean normalized TWD = 59.9J/kgFFW vs 84.6J/kgFFW for controls at 200 degrees/sec). The normalized PT at 50 degrees/sec and TWD at 200 degrees/sec were lower in the males with testicular damage; also, low age at diagnosis correlated positively with muscle strength and performance. There were no differences in normalized PTs or TWDs between cranial radiation and non-radiation cases, or between growth-hormone-deficient and non-deficient cases, and the patients without cranial radiation or with normal growth hormone secretion still had lower normalized PTs and TWDs than the controls.
CONCLUSIONS: Survivors of childhood malignancies have decreased maximal trunk muscle strength and performance. The etiology of this effect remains unclear, but young age at diagnosis, as well as serum testosterone levels in male survivors, evidently influence muscle strength and performance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7487450     DOI: 10.1016/s0003-9993(95)81033-1

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  8 in total

Review 1.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 2.  Frailty in childhood cancer survivors.

Authors:  Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland
Journal:  Cancer       Date:  2014-12-19       Impact factor: 6.860

3.  Physical performance limitations among adult survivors of childhood brain tumors.

Authors:  Kirsten K Ness; E Brannon Morris; Vikki G Nolan; Carrie R Howell; Laura S Gilchrist; Marilyn Stovall; Cheryl L Cox; James L Klosky; Amar Gajjar; Joseph P Neglia
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

4.  Skeletal Muscle and Childhood Cancer: Where are we now and where we go from here.

Authors:  Chelsea G Goodenough; Robyn E Partin; Kirsten K Ness
Journal:  Aging Cancer       Date:  2021-05-20

5.  After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.

Authors:  Celena Scheede-Bergdahl; R Thomas Jagoe
Journal:  Front Pharmacol       Date:  2013-04-19       Impact factor: 5.810

6.  Strength capacity in young patients who are receiving maintenance therapy for acute lymphoblastic leukemia: a case-control study.

Authors:  Mavi Diehl Muratt; Maria Beatriz Perondi; Julia Maria D'Andréa Greve; Hamilton Roschel; Ana Lúcia de Sá Pinto; Bruno Gualano
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Physical and functional performance assessment in pediatric oncology: a systematic review.

Authors:  Regine Söntgerath; Julia Däggelmann; Sabine V Kesting; Corina S Rueegg; Torge-Christian Wittke; Simon Reich; Katharina G Eckert; Sandra Stoessel; Carolina Chamorro-Viña; Joachim Wiskemann; Peter Wright; Anna Senn-Malashonak; Vanessa Oschwald; Anne-Marie Till; Miriam Götte
Journal:  Pediatr Res       Date:  2021-04-15       Impact factor: 3.953

Review 8.  Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.

Authors:  Stefania Gorini; Antonella De Angelis; Liberato Berrino; Natalia Malara; Giuseppe Rosano; Elisabetta Ferraro
Journal:  Oxid Med Cell Longev       Date:  2018-03-18       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.